A phase I/II study of CDX-1140, a CD40 agonist, in combination with capecitabine and oxaliplatin (CAPOX) and pembrolizumab in subjects with biliary tract carcinoma: Phase 1 results.

CDX-1140 - Celldex

oxaliplatin - Generic mfg.

capecitabine - Generic mfg.

Keytruda (pembrolizumab) - Merck (MSD)

https://www.asco.org/abstracts-presentations/264082

Tim Greten; Donna Mabry Hrones; Cecilia Monge; Nebojsa Skorupan; David Kleiner; Bradford Wood; Bernadette Redd

Apr 21, 2026